law21090

Chapter 090

2021 -- H 5710 AS AMENDED
Enacted 06/25/2021

A N A C T

RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT

Introduced By: Representatives Baginski, McGaw, Caldwell, and Potter

Date Introduced: February 24, 2021

It is enacted by the General Assembly as follows:

SECTION 1. Section 21-28-3.32 of the General Laws in Chapter 21-28 entitled "Uniform

Controlled Substances Act" is hereby amended to read as follows:

21-28-3.32. Electronic prescription database. [Effective until January 1, 2023.].

(a) The information contained in any prescription-drug-monitoring database maintained by

the department of health pursuant to § 21-28-3.18 of this chapter shall be disclosed only:

(1) To a practitioner who certifies that the requested information is for the purpose of

evaluating the need for, or providing medical treatment to, a current patient to whom the

practitioner is prescribing or considering prescribing a controlled substance;

(2) To a pharmacist who certifies that the requested information is for a current client to

whom the pharmacist is dispensing, or considering dispensing, a controlled substance;

(3) To an authorized designee of the practitioner and/or pharmacist to consult the

prescription-drug-monitoring database on the practitioner's and/or pharmacist's behalf, or to a

medical director of the practitioner's practice for quality improvement activities within the practice,

provided that:

(i) The designee so authorized is employed by the same professional practice or pharmacy;

(ii) The practitioner or pharmacist takes reasonable steps to ensure that such the designee

is sufficiently competent in the use of the database;

(iii) The practitioner or pharmacist remains responsible for ensuring that access to the

database by the designee is limited to authorized purposes as provided for in subsections (a)(1) and

(a)(2);

(iv) The practitioner or pharmacist remains responsible for ensuring access to the database

by the designee occurs in a manner that protects the confidentiality of information obtained from

the database and remains responsible for any breach of confidentiality;

(v) The practitioner or pharmacist terminates the designee's access to the database at the

termination of the designee's employment; and

(vi) The ultimate decision as to whether or not to prescribe or dispense a controlled

substance remains with the practitioner or pharmacist and is reasonably informed by the relevant,

controlled-substance history information obtained from the database;

(4) Pursuant to a valid search warrant based on probable cause to believe a violation of

federal or state criminal law has occurred and that specified information contained in the database

would assist in the investigation of the crime;

(5) By a department employee to a certified law enforcement prescription drug diversion

investigator of a qualified law enforcement agency for use in an investigation.

(i) A certified law enforcement prescription drug diversion investigator shall provide to the

department the following information in order to receive information from the database:

(A) The identification credentials assigned by the department; and

(B) The case number of the investigation.

(ii) A qualified law enforcement agency shall submit to the department quarterly reports of

the data received by all certified law enforcement prescription drug diversion investigators in the

qualified law enforcement agency, including, without limitation:

(A) Written verification that the inquiries were part of a lawful prescription drug diversion

investigation as provided to the department through the case number of the investigation; and

(B) A brief description of each case closed during that quarter for which the qualified law

enforcement agency used information from the database; and

(iii) The department shall:

(A) Create a verification form for use under subsection (a)(5)(ii)(A) of this section; and

(B) Make the verification form available annually to the qualified law enforcement agency.

(iv) The verification form under subsection (a)(5)(ii)(A) of this section shall be submitted

to the department within thirty (30) days of receipt of the form by the qualified law enforcement

agency.

(v) Failure to submit a verification form under subsection (a)(5)(iv) of this section shall

result in the immediate suspension of disclosure of information from the database by the department

to the qualified law enforcement agency and its certified law enforcement prescription drug

diversion investigators until a determination is made by the department to allow continued

disclosure.

(vi) The director shall, beginning January 1, 2018, and annually thereafter, review

disclosure of information pursuant to subsection (a)(5) of this section. Thereafter, the disclosure of

information pursuant to subsection (a)(5) of this section shall automatically renew for successive

one-year terms unless the director provides written notice to:

(A) The qualified law enforcement agencies; and

(B) The speaker of the house and the president of the senate, at least sixty (60) days in

advance of the then-existing term's end, that the department wishes to discontinue providing

information from the database pursuant to this subsection. The director may reinstitute disclosure

by providing written notice to the same parties;

(6) To a patient who requests his or her own prescription information, or the parent or legal

guardian of a minor child who requests the minor child's prescription information;

(7) To a health professional regulatory board that documents, in writing, that the requested

information is necessary for an investigation related to licensure, renewal, or disciplinary action

involving the applicant, licensee, or registrant to whom the requested information pertains;

(8) To any vendor or contractor with whom the department has contracted, pursuant to state

purchasing law and regulations in the contracting of vendors, to establish or maintain the electronic

system of the prescription-drug-monitoring database;

(9) To public or private entities for statistical, research, or educational purposes, after

removing the patient and prescriber information that could be used to identify individual patients.

This shall not include entities receiving a waiver from the institutional review board; or

(10) To any vendor, agent, contractor, or designee who or that operates an electronic health

record or clinical-management system for the purpose of sharing data with practitioners,

pharmacists, or licensed healthcare facilities or designees.

(b) Information stored in the prescription-drug-monitoring database shall include only the

following:

(1) Patient's first and last name and/or patient identification number; provided, however,

the patient's social security number shall not be recorded in whole or in part, patient sex, patient

date of birth, and patient address;

(2) Prescribing practitioner's name and Drug Enforcement Administration prescriber-

information number;

(3) Prescribing practitioner's office or hospital contact information;

(4) Prescription name, prescription number, prescription species code, national drug code

number, prescription dosage, prescription quantity, days' supply, new-refill code, number of refills

authorized, date the prescription was written, date the prescription was filled, payment type;

provided, however, no credit card number shall be recorded in whole or in part; and

(5) The Drug Enforcement Administration pharmacy number of the pharmacy filling the

prescription.

prescription-drug-monitoring database to that patient, at no cost to the patient, within thirty (30)

business days after the department receives a written request from the patient for the information.

This information shall include the records maintained by the department pursuant to subsection (e).

Notwithstanding the above, the department may, at the request of the law-enforcement agency,

withhold, for up to sixty (60) days following the conclusion of a law-enforcement investigation that

has been confirmed by the department, the disclosure to the patient that information has been

obtained pursuant to subsections (a)(4) and (a)(5) of this section.

(d) A patient may request, from the dispensing pharmacy, correction of any inaccurate

information contained within the prescription-drug-monitoring database in accordance with the

procedure specified by § 5-37.3-5(c).

(e) The department shall, for the period of time that prescription information is maintained,

maintain records of the information disclosed through the prescription-drug-monitoring database,

including, but not limited to:

(1) The identity of each person who requests or receives information from the prescription-

drug-monitoring database and the organization, if any, the person represents;

(2) The information released to each person or organization and the basis for its release

under subsection (a); and

(3) The dates the information was requested and provided.

(f) Prescription information contained within the prescription-drug-monitoring database

shall be removed no later than five (5) years from the date the information is entered into the

database. Records in existence prior to the enactment of this section shall be removed no later than

ten (10) years from the date the information is entered into the database.

(g) The department shall promptly notify any affected individual of an improper disclosure

of information from the prescription-drug-monitoring database or a breach in the security of the

prescription-drug-monitoring database that poses a significant risk of disclosure of patient

information to an unauthorized individual.

(h) At the time of signing a prescription that is required by the department to be entered

into the prescription-drug-monitoring database, the prescribing practitioner shall inform the patient

in writing of the existence of the prescription-drug-monitoring database; the patient's right to access

his or her own prescription information; and the name and contact information of the agency

operating the program.

(i) No person shall access information in the prescription-monitoring-database except to

the extent and for the purposes authorized by subsection (a).

(j) In any civil action allowing a violation of this chapter, the court may award damages,

including punitive damages, and reasonable attorneys' fees and costs to a prevailing plaintiff, and

injunctive and any other appropriate relief.

(k) Any pharmacist who, in his or her professional judgment, refuses to fill a prescription

based on information contained within the prescription-drug-monitoring database shall inform the

prescribing physician within twenty-four (24) hours.

(l) All practitioners shall, as a condition of the initial registration or renewal of the

practitioner's authority to prescribe controlled substances, register with the prescription-drug-

monitoring database maintained by the department of health.

(m) The prescription-monitoring program shall be reviewed prior to starting any opioid. A

prescribing practitioner, or designee as authorized by subsection (a)(3) of this section, shall review

the prescription-monitoring program prior to refilling or initiating opioid therapy with an

intrathecal pump. For patients the prescribing practitioner is maintaining on continuous opioid

therapy for pain for three (3) months or longer, the prescribing practitioner shall review information

from the prescription-monitoring program at least every three (3) months. Documentation of that

review shall be noted in the patient's medical record.

(n) The department shall improve the usefulness and value of the prescription-drug-

monitoring database program by increasing its analytical functionality, timeliness, and scope, such

as by:

(1) Utilizing data from additional data sources as permissible under state and federal

statutes;

(2) Analyzing information submitted to the prescription-drug-monitoring database to

ensure that prescription data collected from dispensing pharmacists is readily accessible for a given

patient; to identify unusual or aberrant patterns of prescribing, dispensing, or receiving controlled

substances; and to generate an automatic alert when such patterns arise to automate standard

reports; and to provide ad hoc reports on a real-time basis on this data as well as other data feeds.

These reports shall comply with the patient confidentiality requirements of federal and state law;

(3) Developing regulations to ensure that prescription-drug-monitoring analyses are

updated and disseminated regularly to appropriate officials and that summary reports are provided

to the general assembly on or before February 1st of each year. Given the intent to decrease the

number of Rhode Island citizens affected by opioid use, the department shall provide an interim

report on the status of the directives included herein and any progress made as of October 1, 2016.

In the development of said the regulations, the department may include any of the following

analytical functions, within the boundaries of patient confidentiality rights under state and federal

law:

(i) Consolidate raw prescription data collected from dispensing pharmacists into a single

view of all prescriptions filled for a given patient;

(ii) Identify unusual or aberrant patterns of prescribing controlled substances, by relevant

prescriber attributes, and generate an automatic alert when such these patterns arise;

(iii) Identify unusual or aberrant patterns of receiving prescriptions for controlled

substances, by relevant patient attributes, and generate an automatic alert when such these patterns

arise;

(iv) Identify unusual or aberrant patterns of dispensing controlled substances, by relevant

dispenser attributes, and generate an automatic alert when such these patterns arise;

(v) Identify and visually display linkages among prescribers, patients, and dispensers that

can be used to detect any collusive behaviors; and

(vi) The department shall apply for federal funding in support of the goals and objectives

contained in this subsection.

21-28-3.32. Electronic prescription database. [Effective January 1, 2023.].